Pinacidil, a new vasodilator, in the treatment of patients with moderate to severe hypertension.

Abstract

A new vasodilator drug, pinacidil, N'-cyano-N-4-pyridyl-N'-1, 2,2-trimethylpropylguanidine, was studied in an open trial in 15 patients with moderate to severe hypertension. Four patients received pinacidil monotherapy, and in 11 patients it was used with a diuretic or a beta-blocker. In all but one patient normotension was achieved with a mean daily pinacidil dose of 46.7 mg b.i.d. (range 20-100 mg). Side effects were few and were action-related. There was no evidence of early toxicity. Pinacidil is a promising new antihypertensive vasodilator, which deserves further clinical evaluation.

• Authors: K Koliopoulos, D E Papadoyannis, N B Karatzas
• Journal: European journal of clinical pharmacology (Eur J Clin Pharmacol) Vol. 27 Issue 3 Pg. 287-9 ( 1984) ISSN: 0031-6970 [Print] Germany
• PMID: 6510455 (Publication Type: Journal Article)

Chemical References

• Antihypertensive Agents
• Guanidines
• Vasodilator Agents
• Pinacidil

Topics

• Adult
• Aged
• Antihypertensive Agents (adverse effects, therapeutic use)
• Female
• Guanidines (adverse effects, therapeutic use)
• Humans
• Hypertension (drug therapy)
• Male
• Middle Aged
• Pinacidil
• Vasodilator Agents (adverse effects, therapeutic use)